• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by ProMIS Neurosciences Inc.

    5/15/26 7:06:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ProMIS Neurosciences, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    74346M505

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    74346M505


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    895,871.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    895,871.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    895,871.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    74346M505


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    895,871.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    895,871.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    895,871.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    74346M505


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    895,871.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    895,871.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    895,871.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    74346M505


    1Names of Reporting Persons

    Wellington Management Company LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    895,871.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    895,871.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    895,871.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ProMIS Neurosciences, Inc.
    (b)Address of issuer's principal executive offices:

    Suite 200, 1920 Yonge Street, Toronto ON M4S 3E2
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP Number(s):

    74346M505
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Wellington Management Group LLP may be deemed to beneficially own an aggregate of 895,871 shares (the "Shares") of Common Stock, of ProMIS Neurosciences Inc. (the "Issuer"). The 895,871 Shares reported as beneficially owned on this Schedule 13G consists of (i) 696,378 Shares held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P., (ii) 199,493 Shares underlying warrants (the "Warrants") held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. The securities beneficially owned by each Filer excludes 496,885 Shares underlying Warrants which contain an issuance limitation that prohibits the holder from exercising the Warrants to the extent that after giving effect to such issuance after the exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the other Filers) would beneficially own in excess of 9.99% of the Shares outstanding immediately after giving effect to the issuance of the Shares issuable upon exercise of the Warrants. As a result, Wellington Management Group LLP beneficially owns 9.99% of the outstanding Shares of the Issuer. Ownership percentages are based on approximately 8,967,693 shares of Common Stock outstanding, reported by the Issuer in its 10-K filed with the SEC on March 25, 2026.
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Wellington Biomedical Innovation Master Investors (Cayman) II L.P. Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:05/15/2026
     
    Wellington Group Holdings LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:05/15/2026
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:05/15/2026
     
    Wellington Management Company LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:05/15/2026
    Get the next $PMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wyman William W

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    5/22/26 4:35:46 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Williams Eugene

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    5/22/26 4:35:15 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Warma Neil K

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    5/22/26 4:34:42 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProMIS Neurosciences to Participate in Upcoming Conferences in June

    CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings. Conference details below:Jefferies Global Healthcare Conference, June 2-4, 2026Location: New York, NYPresentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ETWebcast link: Click here.Virtual Alzheimer's R&D Day, organized by Wolfe Research, June 4, 2026Presentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.

    5/28/26 10:13:28 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

    Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. The planned interim analysis is expected to include a qualitative assessment of aggregated safety data, including amyloid-related imaging abnormalities (ARIA) incidence, as well as key biomarker trends acros

    5/12/26 6:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

    PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso

    3/25/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    SEC Filings

    View All

    SEC Form S-8 filed by ProMIS Neurosciences Inc.

    S-8 - ProMIS Neurosciences Inc. (0001374339) (Filer)

    5/29/26 4:15:40 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

    5/20/26 4:30:26 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by ProMIS Neurosciences Inc.

    SCHEDULE 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    5/15/26 8:55:38 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirwin Patrick D. bought $45,320 worth of shares (4,000 units at $11.33) (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    4/23/26 9:25:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Eugene bought $48,800 worth of shares (2,000 units at $24.40), increasing direct ownership by 19% to 12,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/6/26 7:28:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Eugene bought $92,420 worth of shares (4,000 units at $23.11), increasing direct ownership by 63% to 10,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/4/26 6:08:32 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    View All

    ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

    Appointment reinforces ProMIS Neurosciences' strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer's program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group's Public Equity strategy, has joined the Company's Board of Directors. Dr. Alex has a highly distinguished Wall Street career spanning multiple leadership positions at public market

    10/22/25 7:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

    5/14/24 4:01:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

    4/1/24 4:15:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Financials

    Live finance-specific insights

    View All

    ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

    Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. The planned interim analysis is expected to include a qualitative assessment of aggregated safety data, including amyloid-related imaging abnormalities (ARIA) incidence, as well as key biomarker trends acros

    5/12/26 6:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

    PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso

    3/25/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 4:56:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ProMIS Neurosciences Inc.

    SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 3:36:04 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/6/24 4:15:57 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care